Screener
Roivant Sciences ROIV Gain on litigation settlement
Gain on litigation settlement at other companies
Other financials
Where this comes from
Reported directly by Roivant Sciences in its filing.
Tagged under the XBRL concept us-gaap:LitigationSettlementGain.
The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001635088-26-000090
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 |
|---|---|---|
| Research and development (includes $8,721 and $11,099 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively) | 202,016 | 152,919 |
| General and administrative (includes $74,621 and $71,079 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively) | 165,527 | 134,019 |
| Total operating expenses | 367,827 | 287,092 |
| Gain on litigation settlement | 392 | — |
| Loss from operations | (365,993) | (284,922) |
| Change in fair value of investments | (36,637) | 19,125 |
| Change in fair value of liability instruments | — | 2,329 |
| Interest income | (36,922) | (48,322) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Roivant Sciences's gain on litigation settlement?
- Roivant Sciences (ROIV) reported gain on litigation settlement of $392K in Q2 2026.
- What does gain on litigation settlement mean?
- This metric represents non-recurring income recognized from the successful resolution of legal disputes or settlements. It reflects inflows that are outside the scope of normal operating activities and do not represent sustainable revenue streams. Investors should treat these gains as one-time events that temporarily improve net income without indicating underlying business growth.
Ask your AI about Roivant Sciences's gain on litigation settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude